New hope for Hard-to-Treat colorectal cancer: targeted combo trial launches
Disease control
Ongoing
This early-phase trial tests a new drug called JAB-21822, which targets a specific genetic mutation (KRAS G12C), combined with standard chemotherapy and bevacizumab. The study includes 30 Chinese patients with advanced colorectal cancer that has not responded to first-line treatm…
Phase: PHASE1 • Sponsor: Jian Li • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC